Excluded untreated patients or patients who missed follow‐up and patients with EGFR 20 ins mutation, a total of 139 advanced NSCLC patients with non‐ex 20 ins uncommon EGFR mutation were enrolled in this study and divided into four groups according to their first‐line therapy: first‐generation EGFR‐TKI group (n = 41), afatinib group (n = 43), osimertinib group (n = 36), and chemotherapy group (n = 19). This evidence concerns the gene EGFR and non-small cell lung carcinoma.